A novel approach to the discovery of survival biomarkers in glioblastoma using a joint analysis of DNA methylation and gene expression

Epigenetics

Volumn 9, Issue 6, 2014, Pages 873-883

  Smith, Ashley A ^a   Huang, Yen Tsung ^b   Eliot, Melissa ^b   Houseman, E Andres ^c   Marsit, Carmen J ^d   Wiencke, John K ^e   Kelsey, Karl T ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; DNA methylation; Gene expression; Glioma; Mediation analysis

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; SURVIVAL; VERY ELDERLY; ADOLESCENT; BRAIN TUMOR; CANCER STAGING; CHILD; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHILD; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; SURVIVAL RATE; YOUNG ADULT;

EID: 84901799710     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.28571     Document Type: Article

References (53)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492-507; PMID:18669428; http://dx.doi.org/10.1056/NEJMra0708126
2. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9:157-73; PMID:16530701; http://dx.doi.org/10.1016/j. ccr.2006.02.019
3. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-8; PMID:18772890; http://dx.doi. org/10.1038/nature07385
4. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al.; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17:98-110; PMID:20129251; http://dx.doi.org/10.1016/j.ccr.2009.12.020
5. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013; 45:1141-9; PMID:23917401; http://dx.doi.org/10.1038/ ng.2734
6. Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, Marsit CJ, Wiemels JL, Nelson HH, Karagas MR, Wrensch MR, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 2011; 103:143-53; PMID:21163902; http://dx.doi.org/10.1093/jnci/ djq497
7. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009; 1:239-59; PMID:20495664; http://dx.doi.org/10.2217/epi.09.33
8. Lopez-Serra P, Esteller M. DNA methylationassociated silencing of tumor-suppressor microRNAs in cancer. Oncogene 2012; 31:1609-22; PMID:21860412; http://dx.doi.org/10.1038/ onc.2011.354
9. Wan J, Oliver VF, Zhu H, Zack DJ, Qian J, Merbs SL. Integrative analysis of tissue-specific methylation and alternative splicing identifies conserved transcription factor binding motifs. Nucleic Acids Res 2013; 41:8503-14; PMID:23887936; http:// dx.doi.org/10.1093/nar/gkt652
10. Icli B, Wara AK, Moslehi J, Sun X, Plovie E, Cahill M, Marchini JF, Schissler A, Padera RF, Shi J, et al. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/ SMAD1 signaling. Circ Res 2013; 113:1231-41; PMID:24047927; http://dx.doi.org/10.1161/ CIRCRESAHA.113.301780
11. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al.; Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17:510-22; PMID:20399149; http://dx.doi.org/10.1016/j.ccr.2010.03.017
12. Rivenbark AG, Coleman WB. Dissecting the molecular mechanisms of cancer through bioinformatics-based experimental approaches. J Cell Biochem 2007; 101:1074-86; PMID:17372928; http://dx.doi.org/10.1002/jcb.21283
13. Ferté C, Trister AD, Huang E, Bot BM, Guinney J, Commo F, Sieberts S, André F, Besse B, Soria JC, et al. Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. Clin Cancer Res 2013; 19:4315-25; PMID:23780890; http://dx.doi. org/10.1158/1078-0432.CCR-12-3937
14. Wang W, Baladandayuthapani V, Morris JS, Broom BM, Manyam G, Do KA. iBAG: integrative Bayesian analysis of high-dimensional multiplatform genomics data. Bioinformatics 2013; 29:149-59; PMID:23142963; http://dx.doi.org/10.1093/ bioinformatics/bts655
15. Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F, Saikali S, Hamlat A, Riffaud L, Menei P, et al. DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics 2010; 11:701; PMID:21156036; http://dx.doi.org/10.1186/1471-2164-11-701
16. Rao SK, Edwards J, Joshi AD, Siu IM, Riggins GJ. A survey of glioblastoma genomic amplifications and deletions. J Neurooncol 2010; 96:169-79; PMID:19609742; http://dx.doi.org/10.1007/ s11060-009-9959-4
17. Chattopadhyay S, Tracy E, Liang P, Robledo O, Rose-John S, Baumann H. Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. J Biol Chem 2007; 282:3014-26; PMID:17148439; http:// dx.doi.org/10.1074/jbc.M609655200
18. Priester M, Copanaki E, Vafaizadeh V, Hensel S, Bernreuther C, Glatzel M, Seifert V, Groner B, Kögel D, Weissenberger J. STAT3 silencing inhibits glioma single cell infiltration and tumor growth. Neuro Oncol 2013; 15:840-52; PMID:23486688; http:// dx.doi.org/10.1093/neuonc/not025
19. Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci 2013; 14:265-77; PMID:23481483; http://dx.doi. org/10.1038/nrn3468
20. Bonomini F, Rezzani R. Aquaporin and blood brain barrier. Curr Neuropharmacol 2010; 8:92-6; PMID:21119879; http://dx.doi. org/10.2174/157015910791233132
21. Wolburg H, Noell S, Fallier-Becker P, Mack AF, Wolburg-Buchholz K. The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med 2012; 33:579-89; PMID:22387049; http://dx.doi. org/10.1016/j.mam.2012.02.003
22. El Hindy N, Bankfalvi A, Herring A, Adamzik M, Lambertz N, Zhu Y, Siffert W, Sure U, Sandalcioglu IE. Correlation of aquaporin-1 water channel protein expression with tumor angiogenesis in human astrocytoma. Anticancer Res 2013; 33:609-13; PMID:23393355
23. Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 2005; 434:786-92; PMID:15815633; http:// dx.doi.org/10.1038/nature03460
24. Sepramaniam S, Armugam A, Lim KY, Karolina DS, Swaminathan P, Tan JR, Jeyaseelan K. MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia. J Biol Chem 2010; 285:29223-30; PMID:20628061; http://dx.doi. org/10.1074/jbc.M110.144576
25. Blagitko N, Mergenthaler S, Schulz U, Wollmann HA, Craigen W, Eggermann T, Ropers HH, Kalscheuer VM. Human GRB10 is imprinted and expressed from the paternal and maternal allele in a highly tissue-and isoform-specific fashion. Hum Mol Genet 2000; 9:1587-95; PMID:10861285; http:// dx.doi.org/10.1093/hmg/9.11.1587
26. Monk D, Arnaud P, Frost J, Hills FA, Stanier P, Feil R, Moore GE. Reciprocal imprinting of human GRB10 in placental trophoblast and brain: evolutionary conservation of reversed allelic expression. Hum Mol Genet 2009; 18:3066-74; PMID:19487367; http:// dx.doi.org/10.1093/hmg/ddp248
27. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villén J, Kubica N, Hoffman GR, Cantley LC, Gygi SP, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011; 332:1322-6; PMID:21659605; http://dx.doi.org/10.1126/ science.1199484
28. Nord H, Hartmann C, Andersson R, Menzel U, Pfeifer S, Piotrowski A, Bogdan A, Kloc W, Sandgren J, Olofsson T, et al. Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. Neuro Oncol 2009; 11:803-18; PMID:19304958; http://dx.doi. org/10.1215/15228517-2009-013
29. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003; PMID:15758010; http://dx.doi.org/10.1056/NEJMoa043331
30. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27:5743-50; PMID:19805672; http://dx.doi.org/10.1200/JCO.2009.23.0805
31. Silber JR, Bobola MS, Ghatan S, Blank A, Kolstoe DD, Berger MS. O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 1998; 58:1068-73; PMID:9500473
32. Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, et al. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J Transl Med 2012; 10:250; PMID:23245659; http:// dx.doi.org/10.1186/1479-5876-10-250
33. Zheng S, Houseman EA, Morrison Z, Wrensch MR, Patoka JS, Ramos C, Haas-Kogan DA, McBride S, Marsit CJ, Christensen BC, et al. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro Oncol 2011; 13:280-9; PMID:21339190; http://dx.doi.org/10.1093/neuonc/noq190
34. Costa BM, Caeiro C, Guimarães I, Martinho O, Jaraquemada T, Augusto I, Castro L, Osório L, Linhares P, Honavar M, et al. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. Oncol Rep 2010; 23:1655-62; PMID:20428822
35. Oberstadt MC, Bien-Möller S, Weitmann K, Herzog S, Hentschel K, Rimmbach C, Vogelgesang S, Balz E, Fink M, Michael H, et al. Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. BMC Cancer 2013; 13:617; PMID:24380367; http://dx.doi. org/10.1186/1471-2407-13-617
36. Cecener G, Tunca B, Egeli U, Bekar A, Tezcan G, Erturk E, Bayram N, Tolunay S. The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma. Cell Mol Neurobiol 2012; 32:237-44; PMID:21928112; http://dx.doi. org/10.1007/s10571-011-9753-7
37. Houseman EA, Christensen BC, Yeh RF, Marsit CJ, Karagas MR, Wrensch M, Nelson HH, Wiemels J, Zheng S, Wiencke JK, et al. Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributions. BMC Bioinformatics 2008; 9:365; PMID:18782434; http://dx.doi. org/10.1186/1471-2105-9-365
38. VanderWeele TJ. Causal mediation analysis with survival data. Epidemiology 2011; 22:582-5; PMID:21642779; http://dx.doi.org/10.1097/ EDE.0b013e31821db37e
39. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8:118-27; PMID:16632515; http://dx.doi.org/10.1093/ biostatistics/kxj037
40. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc, B 1995; 57:289-300
41. Ruan B, Pong K, Jow F, Bowlby M, Crozier RA, Liu D, Liang S, Chen Y, Mercado ML, Feng X, et al. Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci U S A 2008; 105:33-8; PMID:18162540; http://dx.doi.org/10.1073/ pnas.0710424105
42. Hanissian SH, Teng B, Akbar U, Janjetovic Z, Zhou Q, Duntsch C, Robertson JH. Regulation of myeloid leukemia factor-1 interacting protein (MLF1IP) expression in glioblastoma. Brain Res 2005; 1047:56-64; PMID:15893739; http://dx.doi.org/10.1016/j. brainres.2005.04.017
43. Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, Garcia R, Demaria S, Newcomb EW. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 2005; 85:328-41; PMID:15716863; http://dx.doi.org/10.1038/ labinvest.3700233
44. Halestrap AP. The SLC16 gene family-structure, role and regulation in health and disease. Mol Aspects Med 2013; 34:337-49; PMID:23506875; http:// dx.doi.org/10.1016/j.mam.2012.05.003
45. Miranda-Gonçalves V, Honavar M, Pinheiro C, Martinho O, Pires MM, Pinheiro C, Cordeiro M, Bebiano G, Costa P, Palmeirim I, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol 2013; 15:172-88; PMID:23258846; http://dx.doi.org/10.1093/neuonc/nos298
46. Colen CB, Shen Y, Ghoddoussi F, Yu P, Francis TB, Koch BJ, Monterey MD, Galloway MP, Sloan AE, Mathupala SP. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia 2011; 13:620-32; PMID:21750656
47. Atkinson GP, Nozell SE, Benveniste ET. NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 2010; 10:575-86; PMID:20367209; http://dx.doi.org/10.1586/ ern.10.21
48. Smith SJ, Tilly H, Ward JH, Macarthur DC, Lowe J, Coyle B, Grundy RG. CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathol 2012; 124:99-110; PMID:22311740; http://dx.doi.org/10.1007/s00401-012-0952-1
49. Akhtar S, McIntosh P, Bryan-Sisneros A, Barratt L, Robertson B, Dolly JO. A functional spliced-variant of beta 2 subunit of Kv1 channels in C6 glioma cells and reactive astrocytes from rat lesioned cerebellum. Biochemistry 1999; 38:16984-92; PMID:10606534; http://dx.doi.org/10.1021/bi992114x
50. Yang X, Zhang Y, Li S, Liu C, Jin Z, Wang Y, Ren F, Chang Z. Rab21 attenuates EGF-mediated MAPK signaling through enhancing EGFR internalization and degradation. Biochem Biophys Res Commun 2012; 421:651-7; PMID:22525675; http://dx.doi. org/10.1016/j.bbrc.2012.04.049
51. Totong R, Schell T, Lescroart F, Ryckebüsch L, Lin YF, Zygmunt T, Herwig L, Krudewig A, Gershoony D, Belting HG, et al. The novel transmembrane protein Tmem2 is essential for coordination of myocardial and endocardial morphogenesis. Development 2011; 138:4199-205; PMID:21896630; http://dx.doi. org/10.1242/dev.064261
52. Smith KA, Lagendijk AK, Courtney AD, Chen H, Paterson S, Hogan BM, Wicking C, Bakkers J. Transmembrane protein 2 (Tmem2) is required to regionally restrict atrioventricular canal boundary and endocardial cushion development. Development 2011; 138:4193-8; PMID:21896629; http://dx.doi. org/10.1242/dev.065375
53. Halestrap AP, Meredith D. The SLC16 gene familyfrom monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch 2004; 447:619-28; PMID:12739169; http://dx.doi.org/10.1007/s00424-003-1067-2